|
| |
NUCL:CYTO SEGMENTATION IN HCS IMAGING ENABLED BY FAR-RED DYE
Scientific presentations at the recent HCA Europe conference in Prague confirm
the nucleic acid-binding dye DRAQ5™ as counterstain of choice for cell-based
imaging HCS assays. DRAQ5™ rapidly enters live or fixed cells to intensity
discriminate between nuclear and cytoplasmic compartments. The resulting
differential is ideal for compartment segmentation by automated image analysis
tools. This offers new opportunities for cell-based assays where cell location,
cell perimeter, cell shape and cell spread parameters can be used to define the
assay at the single cell. DRAQ5™ permits the reliable tracking of fluorophore-tagged
protein translocations and expression changes in GPCRs, kinases and other
therapeutic targets in drug discovery and in vitro toxicology.
The far-red, nucleic acid binding fluorophore DRAQ5™ avoids emission overlap
with most visible range fluorophores and importantly GFP and related tags. This
simplifies assay development, making it more flexible, enabling multiplexing and
the standardization of one key image-based assay parameter. DRAQ5™ is compatible
with all HCS cell imaging platforms including Opera, IN Cell, ImageXpress and
ArrayScan.
DRAQ5™ assays use one fluorophore to reveal both major cell compartments.
Acquisition of both these and the target protein signals can be done
simultaneously, offering a halving of plate scanning times. UV excitation is
avoided reducing interference from compound auto- and cellular bio-fluorescence.
Ready to use, DRAQ5™ rapidly labels live or fixed cells with little need for
optimization. Staining is stable and insensitive to MDR phenotypes. The simple,
no-wash procedure is already widely used in temporo-spatial, fixed end-point and
homogeneous assays across drug discovery. DRAQ5™ is both chemically stable and
resistant to photo-bleaching. It is compatible with aqueous media and may be
combined with cell fixative to remove a protocol step. DRAQ5™ additionally,
provides DNA content information as recently demonstrated on the Acumen eX3
microplate cytometry platform.
Biostatus offers bespoke presentation of DRAQ5™ to suit the needs of its
high-volume HCS users to further streamline assay protocols and increase
workflow efficiency. These data confirm that DRAQ5™ improves HCS assays -
technically, operationally and financially.
Biostatus Ltd.
Shepshed, Leicestershire UK
+44 (0)1509 558163
enquiry@biostatus.com
www.biostatus.com
<Image attached / other format available on request>
PRESS CONTACT:
Roy Edward
Sales & Mktg. Director, Biostatus Ltd
SKYPE: roy.edward.biostatus MOB: 07765 533615 TEL: 01509 558163; roy@biostatus.com;
www.biostatus.com
Co. #: 3079239. Regd. in England & Wales. Regd. office: 56 Charnwood Road,
Shepshed, LE12 9NP, UK.
| |
|
